178 related articles for article (PubMed ID: 29733681)
1. Comparative Performance of Breast Cancer Human Epidermal Growth Factor Receptor 2 Fluorescence In Situ Hybridization and Brightfield In Situ Hybridization on College of American Pathologists Proficiency Tests.
Geiersbach KB; Bridge JA; Dolan M; Jennings LJ; Persons DL; Souers RJ; Tsuchiya KD; Vasalos PH; Moncur JT
Arch Pathol Lab Med; 2018 Oct; 142(10):1254-1259. PubMed ID: 29733681
[TBL] [Abstract][Full Text] [Related]
2. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
[TBL] [Abstract][Full Text] [Related]
3. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
[TBL] [Abstract][Full Text] [Related]
4. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Wolff AC; Hammond ME; Schwartz JN; Hagerty KL; Allred DC; Cote RJ; Dowsett M; Fitzgibbons PL; Hanna WM; Langer A; McShane LM; Paik S; Pegram MD; Perez EA; Press MF; Rhodes A; Sturgeon C; Taube SE; Tubbs R; Vance GH; van de Vijver M; Wheeler TM; Hayes DF; ;
J Clin Oncol; 2007 Jan; 25(1):118-45. PubMed ID: 17159189
[TBL] [Abstract][Full Text] [Related]
5. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Wolff AC; Hammond ME; Schwartz JN; Hagerty KL; Allred DC; Cote RJ; Dowsett M; Fitzgibbons PL; Hanna WM; Langer A; McShane LM; Paik S; Pegram MD; Perez EA; Press MF; Rhodes A; Sturgeon C; Taube SE; Tubbs R; Vance GH; van de Vijver M; Wheeler TM; Hayes DF;
Arch Pathol Lab Med; 2007; 131(1):18-43. PubMed ID: 19548375
[TBL] [Abstract][Full Text] [Related]
6. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
Wolff AC; Hammond MEH; Allison KH; Harvey BE; Mangu PB; Bartlett JMS; Bilous M; Ellis IO; Fitzgibbons P; Hanna W; Jenkins RB; Press MF; Spears PA; Vance GH; Viale G; McShane LM; Dowsett M
Arch Pathol Lab Med; 2018 Nov; 142(11):1364-1382. PubMed ID: 29846104
[TBL] [Abstract][Full Text] [Related]
7. Dual-color dual-hapten in situ hybridization (D-DISH) - Comparison with fluorescence in situ hybridization (FISH) for HER2/neu testing in breast cancer.
Gajaria PK; Tambe S; Pai T; Patil A; Desai SB; Shet TM
Indian J Pathol Microbiol; 2020; 63(2):194-199. PubMed ID: 32317514
[TBL] [Abstract][Full Text] [Related]
8. Impact of 2013 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2 Fluorescent In Situ Hybridization Testing in Breast Cancers : Experience From a National Reference Laboratory.
Gulbahce HE
Am J Clin Pathol; 2017 Oct; 148(4):308-313. PubMed ID: 28967951
[TBL] [Abstract][Full Text] [Related]
9. Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With
Hoda RS; Brogi E; Xu J; Ventura K; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
Arch Pathol Lab Med; 2020 May; 144(5):597-601. PubMed ID: 31647316
[TBL] [Abstract][Full Text] [Related]
10. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
Lim SJ; Cantillep A; Carpenter PM
Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Pathologic Features Associated With Invasive Breast Carcinoma With 2018 American Society of Clinical Oncology/College of American Pathologists In Situ Hybridization Group 2 Results (Human Epidermal Growth Factor Receptor 2 [HER2]/Chromosome 17 Centromere [CEP17] Ratio ≥2.0 and Average HER2 Copy Number <4.0).
Hoda RS; Zarei S; McIntire PJ; Sprague C; Mekhail Y; Carlson DL; Komforti MK; Downs-Kelly EP
Arch Pathol Lab Med; 2022 Jun; 146(6):701-709. PubMed ID: 34559875
[TBL] [Abstract][Full Text] [Related]
12. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
[TBL] [Abstract][Full Text] [Related]
13. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
[TBL] [Abstract][Full Text] [Related]
14. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists.
Carbone A; Botti G; Gloghini A; Simone G; Truini M; Curcio MP; Gasparini P; Mangia A; Perin T; Salvi S; Testi A; Verderio P
J Mol Diagn; 2008 Nov; 10(6):527-36. PubMed ID: 18832456
[TBL] [Abstract][Full Text] [Related]
15. HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.
Press MF; Sauter G; Buyse M; Fourmanoir H; Quinaux E; Tsao-Wei DD; Eiermann W; Robert N; Pienkowski T; Crown J; Martin M; Valero V; Mackey JR; Bee V; Ma Y; Villalobos I; Campeau A; Mirlacher M; Lindsay MA; Slamon DJ
J Clin Oncol; 2016 Oct; 34(29):3518-3528. PubMed ID: 27573653
[TBL] [Abstract][Full Text] [Related]
16. Institutional quality assurance for breast cancer HER2 immunohistochemical testing: identification of outlier results and impact of simultaneous fluorescence in situ hybridization cotesting.
Green IF; Zynger DL
Hum Pathol; 2015 Dec; 46(12):1842-9. PubMed ID: 26412217
[TBL] [Abstract][Full Text] [Related]
17. Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 testing guidelines: a 3-year comparison of validation procedures.
Dyhdalo KS; Fitzgibbons PL; Goldsmith JD; Souers RJ; Nakhleh RE
Arch Pathol Lab Med; 2014 Jul; 138(7):876-84. PubMed ID: 24978913
[TBL] [Abstract][Full Text] [Related]
18. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists.
Dietel M; Ellis IO; Höfler H; Kreipe H; Moch H; Dankof A; Kölble K; Kristiansen G
Virchows Arch; 2007 Jul; 451(1):19-25. PubMed ID: 17562074
[TBL] [Abstract][Full Text] [Related]
19. A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.
Nitta H; Kelly BD; Padilla M; Wick N; Brunhoeber P; Bai I; Singh S; Ranger-Moore J; Bieniarz C; Tsuda H; Grogan TM
Diagn Pathol; 2012 May; 7():60. PubMed ID: 22647525
[TBL] [Abstract][Full Text] [Related]
20. Comparative Analysis of Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer According to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations.
Hanna WM; Slodkowska E; Lu FI; Nafisi H; Nofech-Mozes S
J Clin Oncol; 2017 Sep; 35(26):3039-3045. PubMed ID: 28445098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
